Aleksandr Petrov, Chairman of the Board of Directors of OOO “Zavod Medsintez,” has stated the risk of disappearance of drugs for the treatment of female infertility from the Russian market, TASS reports. At the moment, most drugs for women’s reproductive health in Russia are imported, and if such supplies stop, IVF programs will become impossible.
Petrov said that Ural-based Zavod Medsintez has already started the production of recombinant follicle stimulating hormone and is ready to produce two more drugs in the near future.
“There is a shortage of raw materials in the production of human chorionic gonadotropin, and we will produce this hormone using biotechnology, which is also an import substitution project,” Aleksandr Petrov added.
Medsintez announced its intention to expand the range of IVF drugs back in August 2022. “The launch of a drug normally takes from three to five years, depending on clinical trials,” Petrov said at the time, adding that clinical trials of these drugs will be held in Yekaterinburg.
